Neurodegenerative Dementias


Authors: I. Rektorová
Authors‘ workplace: Centrum pro kognitivní poruchy a demence, I. neurologická klinika LF MU a FN u sv. Anny v Brně
Published in: Cesk Slov Neurol N 2009; 72/105(2): 97-109
Category: Minimonography

Overview

An article is focused on evaluati on and diagnostics of a patient with cognitive deficit and dementia. Mild cognitive impairment is characterized and a brief review of the most common types of neurodegenerative dementias is provided: Alzheimer’s disease, dementia with Lewy bodies/ Parkinson’s disease dementia, frontotemporal lobar degeneration and Huntington’s disease.

Key words:
dementia – mild cognitive impairment – Alzheimer’s disease – Parkinson’s disease with dementia – dementia with Lewy bodies – frontotemporal dementia – Huntington’s disease


Sources

1. Growdon JH, Rossor MN (eds). The dement as II. Philadelphia: Elsevi er 2007.

2. Rektorová I. Demence. In: Rektor I et al (eds). Centrální poruchy motoriky a demence. Plzeň: Adéla 2003: 10– 33.

3. Hort J, Rusina R et al (eds). Paměť a její poruchy. Paměť z hlediska neurovědního a klinického. Praha: Maxdorf 2007.

4. Ritchie K, Lovestone S. The dementias. Lancet 2002; 360(9347): 1759– 1766.

5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM- IV). Washington: American Psychiatric Association 1994:143– 147.

6. Konrád J. Deprese, pseudodemence, demence. In: Rektorová I (ed). Kognitivní poruchy a demence. Praha: Triton 2007: 21– 28.

7. Rektorová I. Diferenciální diagnostika demencí. Psychiatrie 2004; 3: 216– 224.

8. Folstein MF, Folstein SE, McHughs PR. „Mini Mental State“. A practical method for grading the cognitive state of patients for the clinician. J Psychiatric Res 1975; 12(3): 189– 198.

9. Mathuranath PS, Nestor PJ, Berri os GE, Rakowicz W, Hodges JR. A brief cognitive test battery to differentiate Alzheimer’s disease and frontotemporal dementia. Neurology 2000; 55(11): 1613– 1620.

10. Cummings JL, Mega M, Gray K, Rosenberg-Thompson, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44(12): 2308– 2314.

11. Waldemar G, Dubois B, Emre M, Georges J, Mc-Keith IG, Rossor M et al. Recommendations for the diagnosis and management of Alzheimer‘s disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol 2007; 14(1): e1– e26.

12. Ressner P, Hort J, Rektorová I, Bartoš A, Rusina R, Línek V et al. Doporučené postupy pro diagnostiku Alzheimerovy nemoci a dalších onemocnění spojených s demencí. Cesk Slov Neurol N 2008; 71/ 104(5): 494– 501.

13. Koukolík F, Jirák R. Neurobiologie, klinický obraz, terapie. Praha: Galén 2004.

14. Hort J. Markery demence. In: Rektorová I (ed). Kognitivní poruchy a demence. Praha: Triton 2007: 10– 20.

15. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV et al. Current concepts in mild cognitive impairment. Arch Neurol 2001; 58(12): 1985– 1992.

16. Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56(9): 1133– 1142.

17. Cummings JL. Alzheimer‘s disease. N Engl J Med 2004; 351(1): 56– 67.

18. Matěj R, Koukolík F. Neuropatologie neurodegenerativních demencí. In: Rektorová I (ed). Kognitivní poruchy a demence. Praha: Triton 2007: 89– 108.

19. Imbimbo BP, Lombard J, Pomara N. Pathophysiology of Alzheimer‘s disease. Neuroimaging Clin N Am 2005; 15(4): 727– 753.

20. Scarpini E, Scheltens P, Feldman H. Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol 2003; 2(9): 539– 547.

21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer‘s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer‘s Disease. Neurology 1984; 34(7): 939– 944.

22. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J et al. Research criteria for the diagnosis of Alzheimer‘s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6(8): 734– 746.

23. Consensus report of the Working Group on: Molecular and biochemical markers of Alzheimer’s disease. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol Aging 1998; 19(2): 109– 116.

24. Hort J, Glosová L, Vyhnálek M, Bojar M, Škoda D, Hladíková M. Tau protein a beta amyloid v likvoru u Alzheimerovy choroby. Cesk Slov Neurol N 2007; 70/ 103(1): 30– 36.

25. Bartoš A. Klinické novinky na poli Alzheimerovy nemoci. In: Rektorová I (ed) Kognitivní poruchy a demence. Praha: Triton 2007: 49– 60.

26. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer‘s disease with Pittsburgh Compo und-B. Ann Neurol 2004; 55(3): 306– 319.

27. Rosenberg RN. Immunotherapy for Alzheimer disease: the promise and the problem. Arch Neurol 2005; 62(10): 1506– 1507.

28. Sheardová K, Hort J, Rusina R, Bartoš A, Línek V, Ressner P et al. Doporučené postupy pro léčbu Alzheimerovy nemoci a dalších onemocnění spojených s demencí. Cesk Slov Neurol N 2007; 70/ 103: 589– 597.

29. Rektorová I, Rektor I. Parkinsonský syndrom. In: Rektor I, Rektorová I et al (eds). Centrální poruchy hybnosti v praxi. Movement disorders. Praha: Triton 2003: 21– 70.

30. Rektorová I. Demence u Parkinsonovy nemoci a jiných extrapyramidových onemocnění. In: Růžička E et al (eds). Diferenciální diagnostika a léčba demencí. Příručka pro praxi. Praha: Galén 2003: 99– 112.

31. Rektorová I. Demence u Parkinsonovy nemoci. Čes Ger Rev 2008; 6: 214– 219.

32. Burn DJ, McKeith IG. Current treatment of dementia with Lewy bodies and dementia associated with Parkinson’s disease. Mov Disord 2003; 18 (Suppl 6): S72– S79.

33. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh- Sørensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003; 60(3): 387– 392.

34. Cools R, Swainson R, Owen AM et al. Cognitive dysfunction in non-demented Parkinson’s disease. In: Wolters ECh, Scheltens PH and Berendse HW (eds). Mental Dysfunction in Parkinson’s disease II. Amsterdam: Academic Pharmaceutical Productions 1999: 142– 164.

35. Dubois B, Pillon B. Cognitive deficits in Parkinson’s disease. J Neurol 1997; 244(1): 2– 8.

36. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson’s disease. Brain 1983; 106(2): 257– 270.

37. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 2006; 67(9): 1605– 1611.

38. Janvin CC, Larsen JP, Salmon DP, Galasko D, Hugdahl K, Aarsland D. Cognitive profiles of individual patients with Parkinson‘s disease and dementia: comparison with dementi a with Lewy bodies and Alzheimer‘s disease. Mov Disord 2006; 21(3): 337– 342.

39. Jellinger KA. What is new in degenerative dementi a disorders? Wien Klin Wochenschr 1999; 111(17): 682– 704.

40. McKeith IG, Dickson DW, Emre M, O‘Bri en JT, Feldman H, Cummings J et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12): 1863– 1872.

41. Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA et al. Diagnostic procedures for Parkinson‘s disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007; 22(16): 2314– 2324.

42. Rektorova I, Srovnalova H, Kubikova R, Prasek J. Striatal dopamine transporter imaging correlates with depressivew symptoms and Tower of London task performance in Parkinson’s disease. Mov Disord 2008; 23(11): 1580– 1587.

43. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson‘s disease and Alzheimer‘s disease: similarities and differences. J Alzheimers Dis 2007; 11(4): 509– 519.

44. Rektorová I, Baláž M. Postup u psychotických komplikací Parkinsonovy nemoci. In: Rektor I et al (eds). Parkinsonova nemoc: doporučené postupy diagnostiky a léčby II. Pozdní stadium. Praha: Galén 2004: 23– 25.

45. Rektorová I. Farmakoterapi e Parkinsonovy nemoci. Farmakoterapie 2007; 6: 611– 617.

46. Burton EJ, McKeith IG, Burn DJ, Willi ams ED, O’Bri en JT. Cerebral atrophy in Parkinson‘s disease with and without dementia: a comparison with Alzheimer‘s disease, dementia with Lewy bodies and controls. Brain 2004; 127(4): 791– 800.

47. Nagano–Saito A, Washimi Y, Arahata Y, Kachi T, Lerch JP, Evans AC et al. Cerebral atrophy and its relation to cognitive impairment in Parkinson disease. Neurology 2005; 64: 224– 229.

48. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson‘s disease. Neurobiol Aging 2003; 24(2): 197– 211.

49. Braak H, Rüb U, Jansen Steur EN, Del Tredici K, de Vos RA. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005; 64(8): 1404– 1410.

50. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson‘s disease: a prospective, community-based study. Ann Neurol 2005; 58(5): 773– 776.

51. Rektorová I. Kognitivní a behaviorální poruchy u demence při Parkinsonově nemoci a u demence s Lewyho tělísky. Neurol pro praxi 2004; 1: 15– 21.

52. Williams DR, de Silva R, Paviour DC, Pittman A, Watt HC, Kilford L et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson‘s syndrome and PSP- parkinsonism. Brain 2005; 128(6): 1247– 1258.

53. Burn DJ, O’Brien JT. Use of functional imaging in Parkinsonism and dementia. Mov Disord 2003; 18 (Suppl 6): S88– S95.

54. Rektorova I. DaTSCAN for diagnosis. EPNN Journal 2007; 11(1): 14– 15.

55. Poewe W. Treatment of dementia with Lewy bodies and Parkinson’s disease dementia. Mov Disord 2005; 20 (Suppl 12): S77– S82.

56. Rektorová I. Psychiatrické symptomy Parkinsonovy nemoci: diagnostika a léčba. Neurol pro praxi 2007; 8: 291– 294.

57. Rektorová I. Účinek donepezilu na demenci u Parkinsonovy nemoci a Alzheimerovy nemoci: Pilotní studie. Cesk Slov Neurol N 2004; 67/ 100(5): 359– 363.

58. McKeith IG, Del Ser T, Spano P, Emre M, Wesnes K, Anand R et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo- controlled international study. Lancet 2000; 356(9247): 2031– 2036.

59. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP et al. Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 2004; 351(24): 2509– 2518.

60. Rektorová I. Rivastigmin v léčbě demence u Parkinsonovy nemoci. Remedia 2006; 6: 609– 613.

61. Rektorová I. Frontotemporální lobární degenerace – diagnóza z neuro-psychiatrického pomezí. Neurol pro praxi 2006; 4:199– 202.

62. Rektorová I. Frontotemporální lobární degenerace. In: Rektorová I (ed) Kognitivní poruchy a demence. Praha: Triton 2007: 61– 75.

63. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51(6): 1546– 1554.

64. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ; Work Group on Frontotemporal Dementia and Pick‘s Disease. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick‘s Disease. Arch Neurol 2001; 58(11): 1803– 1809.

65. Hodges JR, Davies RR, Xuereb JH, Casey B, Broe M, Bak TH et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004; 56(3): 399– 406.

66. Kertesz A, McMonagle P, Blair M, Davidson W, Munoz DG. The evolution and pathology of frontotemporal dementia. Brain 2005; 128(9): 1996– 2005.

67. Godbolt AK, Josephs KA, Revesz T, Warrington EK, Lantos P, King A et al. Sporadic and familial dementia with ubiquitin-positive tau-negative inclusions: clinical features of one histopathological abnormality underlying frontotemporal lobar degeneration. Arch Neurol 2005; 62(7): 1097– 1101.

68. Mackenzie IR, Baker M, Pickering-Brown S, Hsiung GY, Lindholm C, Dwosh E et al. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain 2006; 129(11): 3081– 3090.

69. Mott RT, Dickson DW, Trojanowski JQ, Zhukareva V, Lee VM, Forman M et al. Neuropathologic, biochemical, and molecular characterization of the frontotemporal dementias. J Neuropathol Exp Neurol 2005; 64(5): 420– 428.

70. Bigio EH. Update on recent molecular and genetic advances in frontotemporal lobar degeneration. J Neuropathol Exp Neurol 2008; 67(7): 635– 648.

71. Bigio EH. TAR DNA-binding protein-43 in amyotrophic lateral sclerosis, frontotemporal lobar degeneration, and Alzheimer disease. Acta Neuropathol 2008; 116(2): 135– 140.

72. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006; 66(1): 17– 22.

73. Victor M, Ropper AH. Huntington chorea. In: Adams RD, Victor M. Principles of Neurology. 7th ed. Columbus, Ohio: The McGraw-Hill Companies 2001: 1121– 1125.

74. Vonsattel JP, DiFigli a M. Huntington’s disease. J Neuropathol Exp Neurol 1998; 57(5): 369– 384.

75. Roth J, Židovská J, Uhrová T, Doubek P, Havrdová E, Koblihová J et al. Huntingtonova nemoc a etické problémy její diagnostiky. Psychiatrie 2001; 4: 251– 255.

76. Rektorová I. Chorea. In: Rektor I, Rektorová I et al (eds). Centrální poruchy hybnosti v praxi. Movement disorders. Praha: Triton 2003: 103– 107.

77. Claes S, Van Zand K, Legius E, Dom R, Malfroid M et al. Correlations between triplet repeat expansion and clinical features in Huntington’s disease. Arch Neurol 1996; 53(8): 714– 715.

78. Berardelli A, Noth J, Thompson PD, Bollen EL, Curra A, Deuschl G et al. Pathophysiology of chorea and bradykinesia in Huntington’s disease. Mov Dis 1999; 14(3): 398– 403.

Labels
Paediatric neurology Neurosurgery Neurology
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account